Atorvastatin indications and usage: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
* Reduce elevated TG in patients with [[hypertriglyceridemia]] and primary dysbetalipoproteinemia. | * Reduce elevated TG in patients with [[hypertriglyceridemia]] and primary dysbetalipoproteinemia. | ||
* Reduce total-C and LDL-C in patients with homozygous familial [[hypercholesterolemia]] (HoFH). | * Reduce total-C and LDL-C in patients with homozygous familial [[hypercholesterolemia]] (HoFH). | ||
* Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial [[hypercholesterolemia]] after failing an adequate trial of diet therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228 | * Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial [[hypercholesterolemia]] after failing an adequate trial of diet therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228 | publisher = | date = | accessdate = 30 January 2014 }}</ref> | ||
Atorvastatin has not been studied in Fredrickson Types I and V [[dyslipidemia]] | Atorvastatin has not been studied in Fredrickson Types I and V [[dyslipidemia]] | ||
Revision as of 18:24, 30 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Indications and Usage
Atorvastatin is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:
- Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors.
- Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors.
- Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD.
- Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.
- Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia.
- Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH).
- Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy.[1]
Atorvastatin has not been studied in Fredrickson Types I and V dyslipidemia
References
- ↑ "LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC]". Retrieved 30 January 2014.